The FDA has approved a new formulation of OxyContin (oxycodone HCl controlled-release tablets, from Purdue) that has been designed to help discourage misuse and abuse. The reformulated OxyContin is intended to prevent immediate access to the full dose of oxycodone via cutting, chewing, or breaking the tablet. Attempts to dissolve the tablets in liquid result in a gummy substance that cannot be drawn up into a syringe or injected.
The new formulation of OxyContin reduces the likelihood that this drug will be misused and abused, although it can not completely eliminate this possibility as OxyContin can still be abused or misused by simply ingesting larger doses than are recommended.
OxyContin is indicated for the treatment of moderate to severe pain when continuous opioid analgesia is needed for an extended time period.
For more information visit www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm207480.htm.